MONTREAL--(BUSINESS WIRE)--Mimetogen Pharmaceuticals today announced that effective August 31st, 2014, the exclusive option agreement to license an investigational compound in development for the treatment of dry eye syndrome with Bausch + Lomb, has terminated.
Dry eye occurs when the eye does not produce enough tears, or when the tears are not of the correct consistency and evaporate too quickly. Inflammation of the surface of the eye may also occur. If left untreated, the condition can lead to pain, ulcers, or scars on the cornea, and some loss of vision, although permanent loss of vision from dry eye is uncommon. Dry eye can also have a significant impact on quality of life, making it more difficult to perform activities such as using a computer or reading for an extended period of time.
Help employers find you! Check out all the jobs and post your resume. v
